Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1951

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma

Rami Alsharif, MD, Samah Nassereddine, MD, Esma Akin, MD, Donald Karcher, MD, Mitchell Smith, MD PhD, Eduardo Sotomayor, MD, Kieron Dunleavy, MD

Blood (2019) 134 (Supplement_1): 5355.

https://doi.org/10.1182/blood-2019-124081

Published: 2019

Journal Articles

High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?

Miguel Quintela, Iolanda Vieira, Cláudia Moreira, Sérgio Chacim, Nelson Domingues, Isabel Oliveira, Ana Espirito Santo, Maria Ilidia Moreira, Ângelo Martins, Maria Luisa Viterbo, Dulcineia Pereira, Jose Mario Mariz

Blood (2019) 134 (Supplement_1): 5356.

https://doi.org/10.1182/blood-2019-131254

Published: 2019

Journal Articles

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Crystal Watson, MS, Arie Barlev, PharmD, Jodie Worrall, Steve Duff, MS, Rachel Beckerman, PhD

Blood (2019) 134 (Supplement_1): 5826.

https://doi.org/10.1182/blood-2019-122611

Published: 2019

Journal Articles

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Beth Lesher, PharmD, Eleanor Lucas, BA, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5881.

https://doi.org/10.1182/blood-2019-130896

Published: 2019

Journal Articles

Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL)

Zachary West, BS, Kristen Allen, MPH, Caitlin Monroe, MPH, Sharon M. Castellino, MD MSc, Tamara P. Miller, MDMSc

Blood (2019) 134 (Supplement_1): 5809.

https://doi.org/10.1182/blood-2019-131873

Published: 2019

Journal Articles

Long Term Response Evaluation of Newly Diagnosed Chronic Myeloid Leukemia Patients on Imatinib Mesylate in Indian Population over 12 Years

Tara Rajendran, MBBS, Prasad Pramod Rane, MPH, Krishna Prasad, MBBS, MD(Internal MDcine), DM (Oncology)

Blood (2019) 134 (Supplement_1): 5913.

https://doi.org/10.1182/blood-2019-125978

Published: 2019

Journal Articles

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Ryan N Rys, BSc, BA, Dominique Geoffrion, BSc, Christopher Rushton, BSc, Miguel Alcaide, PhD, Raoul Santiago, MDMSc, Koren Kathleen Mann, PhD, Svetlana Dmitrienko, MD PhD, Tina Petrogiannis-Haliotis, MD PhD, Sarit Assouline, MD, Ryan D. Morin, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1608.

https://doi.org/10.1182/blood-2019-127129

Published: 2019

Journal Articles

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

Martin Müller, MSc, Franz Geisslinger, Susanne Gerndt, Ramona Schütz, Yu-Kai Chao, Franz Bracher, Christian Grimm, Angelika Vollmar, Karin Bartel

Blood (2019) 134 (Supplement_1): 2081.

https://doi.org/10.1182/blood-2019-128195

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Julie Devin, PharmD, Tatiana Cañeque, Yea-Lih Lin, PhD, Guillaume Cartron, Philippe Pasero, PhD, Caroline Bret, PhD PharmD, Raphael Rodriguez, Jerome Moreaux, PhD

Blood (2019) 134 (Supplement_1): 3960.

https://doi.org/10.1182/blood-2019-129954

Published: 2019

Journal Articles

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

Nikesh Shah, MD, Franco Castillo-Tokumori, MD, Julio C. Chavez, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Javier Pinilla Ibarz, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 3991.

https://doi.org/10.1182/blood-2019-127291

Published: 2019

Journal Articles

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

Rohit Gupta, BA, Jason H. Rogers, MS, Xin Long, PhD, Geraldo Medrano, BS, Jaime M. Reyes, BS, Michele Redell, MD PhD, Zachary T Ball, PhD, Margaret Goodell, PhD, Rachel E. Rau, MD

Blood (2019) 134 (Supplement_1): 3789.

https://doi.org/10.1182/blood-2019-127209

Published: 2019

Journal Articles

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

Shilpa Paul, PharmD, Koji Sasaki, MD, J Michael Savoy, PharmD, Adam Dipippo, PharmD, Nadya Jammal, PharmD, Kayleigh Marx, PharmD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3810.

https://doi.org/10.1182/blood-2019-130284

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL

Blood (2019) 134 (Supplement_1): 3758.

https://doi.org/10.1182/blood-2019-126910

Published: 2019

Journal Articles

Targeting of Integrin α4/VCAM-1 with AVA4746 Modulates the Redox-Status and Metabolism in ALL and Angiogenesis

Ruan Yongsheng, MD, Enzi Jiang, MD PhD, Hye Na Kim, Heather Ogana, Mo Yang, MD, Deepa Bhojwani, MD, Alan S. Wayne, MD, Yong-Mi Kim, MD MPH, PhD

Blood (2019) 134 (Supplement_1): 3881.

https://doi.org/10.1182/blood-2019-132101

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

The different flavors and splices of MCL

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma

High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL)

Long Term Response Evaluation of Newly Diagnosed Chronic Myeloid Leukemia Patients on Imatinib Mesylate in Indian Population over 12 Years

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL

Targeting of Integrin α4/VCAM-1 with AVA4746 Modulates the Redox-Status and Metabolism in ALL and Angiogenesis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only